GlassScriptPhysician profile
Joseph Nshiewat
NPI 1609223429
$5,406.08
in general payments reported to CMS, 2019-2025
38 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $148 · 2021: $835 · 2022: $516 · 2023: $953 · 2024: $1,614 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $919.26 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $865.56 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $408.52 | 2020-2024 | Xarelto |
| Glaxosmithkline, LLC. | $367.86 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $307.59 | 2021-2024 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $265.44 | 2023-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.24 | 2021-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $214.21 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $193.66 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $142.23 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $137.93 | 2021-2025 | Repatha, Otezla |
| Paratek Pharmaceuticals, INC. | $129.31 | 2023-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $121.07 | 2020-2025 | Farxiga, Breztri |
| Pharmacosmos Therapeutics INC. | $118.73 | 2023 | Monoferric |
| Shield Therapeutics INC | $110.42 | 2024-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Nshiewat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.